Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Whole Exome Sequencing in Children with Sickle Cell Anemia Who Developed Ischemic Stroke Prior to 4 Years of Age Reveals a Strong Association with Inherited Dyslipidemias

John N. Brewin, Riley Cook, MD, Alexander E Smith, PhD, Valentine Brousse, MD PhD, Julie Brent, MD, Sanjay Tewari, FRCPath, MBBS, Baba PD Inusa, MD, Stephan Menzel, MD PhD, David C Rees

Blood (2019) 134 (Supplement_1): 3571.

https://doi.org/10.1182/blood-2019-123764

Published: 2019

Journal Articles

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

Jia Yu, Xuan Yuan, MD MSc, Kang Zhou, Daniel White, Samuel A. Merrill, MD PhD, Robert A. Brodsky, MD

Blood (2018) 132 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2018-99-119445

Published: 2018

Journal Articles

Inhibition of Alternative Complement Pathway in Target Organs Represents a Novel and Effective Approach to Control Gvhd While Sparing GVL Effect

Hung D Nguyen, PhD, Ali Alawieh, MD PhDCandidate, David A Bastian, BS, Anusara Daenthanasanmak, PhD, Steven D Schutt, BS, Supinya Iamsawat, MSc, Yongxia Wu, PhD, Atkinson Carl, PhD, Stephen Tomlinson, PhD, Xue-Zhong Yu, PhD

Blood (2016) 128 (22): 807.

https://doi.org/10.1182/blood.V128.22.807.807

Published: 2016

Journal Articles

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Antonio M Risitano, MD PhD, Michael Storek, Leonardo Sahelijo, MD, Mittie Doyle, Yang Dai, Ilene Ceil Weitz, MD, Judith C.W. Marsh, MD, Modupe Elebute, MBChB, MD, Casey L O'Connell, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Giridharan Ramsingh, MD, Serena Marotta, MD, Andrzej Hellmann, Ante S. Lundberg, MD

Blood (2015) 126 (23): 2137.

https://doi.org/10.1182/blood.V126.23.2137.2137

Published: 2015

Journal Articles

Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience

Katerina Pavenski, MD FRCP, Jerome M. Teitel, MD, Gloria Lim, BSc, MSc, MD, Michelle Sholzberg, MD, Michael Kirschfink, Christoph Licht, MD FRCP(C), FASN

Blood (2014) 124 (21): 4186.

https://doi.org/10.1182/blood.V124.21.4186.4186

Published: 2014

Journal Articles

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Antonio M. Risitano, MD, PhD, Patrizia Ricci, Caterina Pascariello, Maddalena Raia, Christoph Q Schmidt, Yingxue Li, Edimara S Reis, Michela Sica, PhD, Rosario Notaro, MD, Luigi Del Vecchio, MD, Fabrizio Pane, Daniel Ricklin, John D Lambris

Blood (2012) 120 (21): 370.

https://doi.org/10.1182/blood.V120.21.370.370

Published: 2012

Journal Articles

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Antonio M. Risitano, Rosario Notaro, Caterina Pascariello, Michela Sica, Luigi del Vecchio, Christopher J. Horvath, Masha Fridkis-Hareli, Carmine Selleri, Margaret A. Lindorfer, Ronald P. Taylor, Lucio Luzzatto, V. Michael Holers

Blood (2012) 119 (26): 6307–6316.

https://doi.org/10.1182/blood-2011-12-398792

Published: 2012

Includes: Supplemental data

Journal Articles

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome

Nigel J. Francis, Bairbre McNicholas, Atif Awan, Mary Waldron, Donal Reddan, Denise Sadlier, David Kavanagh, Lisa Strain, Kevin J. Marchbank, Claire L. Harris, Timothy H. J. Goodship

Blood (2012) 119 (2): 591–601.

https://doi.org/10.1182/blood-2011-03-339903

Published: 2012

Includes: Supplemental data

Journal Articles

Increased coagulation factor VIII activity in patients with familial hypercholesterolemia

Roeland Huijgen, John J. P. Kastelein, Joost C. M. Meijers

Blood (2011) 118 (26): 6990–6991.

https://doi.org/10.1182/blood-2011-10-386227

Published: 2011

Journal Articles

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, Antonio M. Risitano, Ante S. Lundberg, Christopher J. Horvath, V. Michael Holers

Blood (2011) 118 (17): 4705–4713.

https://doi.org/10.1182/blood-2011-06-359646

Published: 2011

Includes: Supplemental data

Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD

Blood (2010) 116 (21): 638.

https://doi.org/10.1182/blood.V116.21.638.638

Published: 2010

Journal Articles

TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.

Antonio M. Risitano, MD, PhD, V. Michael Holers, Bruno Rotoli

Blood (2009) 114 (22): 158.

https://doi.org/10.1182/blood.V114.22.158.158

Published: 2009

Journal Articles

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

V. Michael Holers, Istvan Mazsaroff, PhD, Hillary Akana, Christopher G. Smith, J. Woodruff Emlen, MD, Russell C. Marians, PhD, Christopher J. Horvath, DVM

Blood (2009) 114 (22): 3021.

https://doi.org/10.1182/blood.V114.22.3021.3021

Published: 2009

Journal Articles

Characterization of complement factor H–related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome

Cynthia Abarrategui-Garrido, Rubén Martínez-Barricarte, Margarita López-Trascasa, Santiago Rodríguez de Córdoba, Pilar Sánchez-Corral

Blood (2009) 114 (19): 4261–4271.

https://doi.org/10.1182/blood-2009-05-223834

Published: 2009

Includes: Supplemental data

Journal Articles

Plasminogen Activator Inhibitor 1 Deficiency Reduces the Progression of Atherosclerosis in a Murine Model of Human Familial Hypercholesterolemia.

Takayuki Iwaki, MD, PhD, Ploplis A. Victoria, Ph.D., Francis J. Castellino, Ph.D.

Blood (2006) 108 (11): 1804.

https://doi.org/10.1182/blood.V108.11.1804.1804

Published: 2006

Journal Articles

Identification of Apolipoprotein E Receptor 2′ as the Low-Density Lipoprotein Receptor on Platelets.

Jan-Willem N. Akkerman, PhD, Suzanne J.A. Korporaal, Ingrid A.M. Relou, PhD, Miranda Van Eck, Martineke Bezemer, Gertie Gorter, Theo J.C. Van Berkel, PhD, Johannes Nimf, PhD, Peter J. Lenting, PhD

Blood (2004) 104 (11): 1549.

https://doi.org/10.1182/blood.V104.11.1549.1549

Published: 2004

NARROW

Whole Exome Sequencing in Children with Sickle Cell Anemia Who Developed Ischemic Stroke Prior to 4 Years of Age Reveals a Strong Association with Inherited Dyslipidemias

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

Inhibition of Alternative Complement Pathway in Target Organs Represents a Novel and Effective Approach to Control Gvhd While Sparing GVL Effect

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome

Increased coagulation factor VIII activity in patients with familial hypercholesterolemia

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

Characterization of complement factor H–related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome

Plasminogen Activator Inhibitor 1 Deficiency Reduces the Progression of Atherosclerosis in a Murine Model of Human Familial Hypercholesterolemia.

Identification of Apolipoprotein E Receptor 2′ as the Low-Density Lipoprotein Receptor on Platelets.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only